Lexeo Therapeutics, Inc. Common Stock

NASDAQ:LXEO

Biotechnology

Healthcare
$2.95 -0.94%

-$0.05 today

Market cap
$244.23M
Beta
1.39
P/E (TTM)
-4.6
EPS (TTM)
-$1.08
52W Low $3.60High $10.99

Volume 1.76M

Average 0.86M

LXEO Free Cash Flow

Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.

Lexeo Therapeutics, Inc. Common StockNASDAQ: LXEO

Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Free cash flow dips below year-ago levels

Q1 FY2026 free cash flow of $21.18M (cash outflow) fell 2.5% year over year, behind the +11.5% change in trailing-twelve-month free cash flow. Sequentially, it rose 5.5% from the prior quarter. Over 3 fiscal years it compounded at +21.3% a year.

Context

  • Free cash flow grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -2.5% toward the trailing-twelve-month pace of +11.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$21.18M+5.5% QoQ
Last fiscal yearDec 2025
-$98.96M+21.2% YoY
LTMMar 2026
-$98.42M+11.5% YoY
Free Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-2.5%——
1 year+21.2%——
3-year CAGR+21.3%——
5-year CAGR——
10-year CAGR——

Free Cash Flow history

USD · from the cash flow

Latest · FY2025
(98.96M) USD
Year-over-year change
-21.2%

Free Cash Flow vs competitors

How LXEO compares with its peers on the latest reported figures

  • LXEO's LTM Mar 2026 free cash flow of $98.42M is the 7th largest of the 11 companies compared; the peer median is $120.63M.
  • Its year-over-year change of +11.5% is the 9th highest of 10, against a peer median of +50.2%.
  • Over three fiscal years its annual growth of +21.3% compares with a peer median of +40.0%.
LXEO Competitors Peer median
Free Cash Flow for LXEO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DBVTDBV Technologies S.A.LTM Mar 2026$151.54M +67.5%+29.0%—
KYTXKyverna Therapeutics, Inc.LTM Mar 2026$150.99M +11.6%+60.9%—
LRMRLarimar Therapeutics, Inc.LTM Mar 2026$131.32M +50.2%+60.0%—
VYGRVoyager Therapeutics, Inc.LTM Mar 2026$129.94M +14.0%+108.0%356.1%
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026$127.3M +121.8%—58.5%
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$113.96M +141.6%——
LXEOLexeo Therapeutics, Inc. Common StockLTM Mar 2026$98.42M +11.5%+21.3%—
SLNSilence Therapeutics plcLTM Mar 2026$65.67M —+2.7%7126.6%
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026$57.66M +45.8%+40.0%—
MREOMereo BioPharma Group plcLTM Mar 2026$26.96M -19.5%-14.1%5391.1%
AMRNAmarin Corporation plcLTM Mar 2026$25.51M +182.6%—11.9%
Peer median (excluding LXEO) $120.63M+50.2%+40.0%356.1%

Competitors are the stored peer set for LXEO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(50.62M)(59.28M)(66.39M)(98.33M)(99.96M)
Depreciation & Amortization13K1.15M1.84M2M379K
Deferred Income Tax00000
Stock-Based Compensation386K1.78M3.04M12.47M12.13M
Change in Working Capital6.04M1.79M1.48M2.73M(9.52M)
Accounts Receivables00000
Inventory00000
Accounts Payables3.02M(426K)(180K)2.38M(1.56M)
Other Working Capital3.03M2.22M1.66M351K(7.95M)
Other Non-Cash Items00530K(23K)(1.6M)
Operating Cash Flow(44.18M)(54.56M)(59.5M)(81.15M)(98.56M)
Capital Expenditures(188K)(901K)(165K)(481K)(397K)
Acquisitions (Net)00000
Purchases of Investments000(93.6M)(195.4M)
Sales of Investments0000105.53M
Other Investing Activities0(229K)(50K)017K
Investing Cash Flow(188K)(901K)(165K)(94.08M)(90.25M)
Debt Repayment0(163K)3.58M(410K)(533K)
Common Stock Issued170K332K100.25M88.71M217.33M
Common Stock Repurchased000(17K)0
Dividends Paid00000
Other Financing Activities(203K)332K(35K)491K0
Financing Cash Flow150.86M189K103.79M88.78M216.8M
Effect of Forex Changes00000
Net Change in Cash106.49M(55.27M)44.13M(86.45M)27.98M
Free Cash Flow(44.37M)(55.46M)(59.66M)(81.63M)(98.96M)

Lexeo Therapeutics, Inc. Common Stock

NASDAQ:LXEO

Intrinsic Alpha fair value

Locked

Current Price

$2.95

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.